<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622864</url>
  </required_header>
  <id_info>
    <org_study_id>HRS-9821-I-101</org_study_id>
    <nct_id>NCT05622864</nct_id>
  </id_info>
  <brief_title>Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerance, Pharmacokinetics and Pharmacodynamics Phase I Study of Increased Doses of Single and Multiple Atomized Inhalation of HRS-9821 Suspension for Inhalation in Healthy People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Hengrui Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Hengrui Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increased safety and tolerance of single and multiple atomized inhalation of HRS-9821&#xD;
      suspension for inhalation doses in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2023</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the incidence and severity of adverse events after single and multiple atomization inhalation of HRS-9821 in healthy subjects</measure>
    <time_frame>About a month from the first medication to the evaluation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the forced expiratory volume in one second (FEV1) of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>2 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the forced expiratory volume in one second (FEV1) of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>4 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the forced expiratory volume in one second (FEV1) of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>6 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the forced expiratory volume in one second (FEV1) of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>12 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the forced expiratory volume in one second (FEV1) of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the average value of FEV1 compared with baseline changes in healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>2 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the average value of FEV1 compared with baseline changes in healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>3 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the average value of FEV1 compared with baseline changes in healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>4 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the average value of FEV1 compared with baseline changes in healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>12 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the average value of FEV1 compared with baseline changes in healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change of FEV1 peak in healthy subjects after single and multiple atomization inhalation of HRS-9821 compared with the baseline</measure>
    <time_frame>About 24 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the force lung capacity（FVC） of healthy subjects after single and multiple atomized inhalation of HRS-9821</measure>
    <time_frame>2 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetics concentration and pharmacokinetic parameters of healthy subjects after single and multiple atomization inhalation of HRS-9821</measure>
    <time_frame>2 weeks after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PartA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS-9821</intervention_name>
    <description>HRS-9821</description>
    <arm_group_label>PartA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS-9821</intervention_name>
    <description>HRS-9821</description>
    <arm_group_label>PartB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign an informed consent forms；&#xD;
&#xD;
          2. Healthy men aged 18-50 (both ends, subject to the signing of the informed consent&#xD;
             form);&#xD;
&#xD;
          3. Weight ≥50 kg，BMI 18-33 kg/m2 (include 33 kg/m2);&#xD;
&#xD;
          4. During the screening period, the vital signs are normal:&#xD;
&#xD;
               -  Shrinkage 90-140 mmHg,&#xD;
&#xD;
               -  diastolic pressure 50-90 mmHg,&#xD;
&#xD;
               -  Heart rate 40-100 times/min;&#xD;
&#xD;
          5. During the screening period, the lung function is normal, that is, the predicted value&#xD;
             of FEV1≥80% and the predicted value of FEV1/FVC≥92%;&#xD;
&#xD;
          6. During screening, the 12-lead ECG is normal or abnormal but has no clinical&#xD;
             significance.&#xD;
&#xD;
          7. Follow the contraceptive requirements within 14 weeks from the beginning of the&#xD;
             consent to the last dose, and do not donate sperm during the consent period;&#xD;
&#xD;
          8. During the study, all research regulations and procedures can be followed, and the&#xD;
             atomization devices used by the research institute can be used correctly;&#xD;
&#xD;
          9. Non-smoking or quitting smoking ≥ 12 months, the previous smoking history &lt; 5 packs of&#xD;
             years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the past 12 weeks, antibiotics have been used for upper and lower respiratory tract&#xD;
             infections, or have a history of respiratory infections within the past 4 weeks;&#xD;
&#xD;
          2. Abnormal laboratory or physical examination results of clinical significance&#xD;
&#xD;
          3. The average value of QTcF for 3 times at screening is ≥450ms;&#xD;
&#xD;
          4. In the past four weeks, there have been blood donations or large blood loss (more than&#xD;
             400 milliliters), or those who intentionally donate blood during the study&#xD;
&#xD;
          5. Accept experimental drugs or use experimental medical devices within 3 months or less&#xD;
             than 5 times the half-life of the drug, whichever is longer;&#xD;
&#xD;
          6. In the past, there were difficulties in collecting blood or could not withstand&#xD;
             intravenous puncture, such as needle halo and blood halo&#xD;
&#xD;
          7. Any organ system has a history of malignant tumors;&#xD;
&#xD;
          8. Known to be allergic to any accessories in the research drug or formulation;&#xD;
&#xD;
          9. Previously known infection of human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV) liver or hepatitis C virus (HCV); or randomized pre-HIV (according to the test&#xD;
             center SOP), treponema pallidum antibody (TPPA), HBV surface antigen or HCV antibody&#xD;
             positive;&#xD;
&#xD;
         10. There is a history of smoking and alcoholism in the 3 months before screening: smoking&#xD;
             (more than 5 cigarettes or equivalent tobacco per day); alcoholism (more than 14 units&#xD;
             of alcohol per week: 1 unit = 360mL of beer, or 25mL of spirits with a concentration&#xD;
             of 40% or more, or 1 glass of wine, 180mL);&#xD;
&#xD;
         11. In the past five years, there has been a history of drug abuse and drug dependence.&#xD;
&#xD;
         12. Before randomization, positive for alcohol or drug abuse or nicotine in urine.&#xD;
&#xD;
         13. During the study, there is a surgical plan or may interfere with the treatment plan&#xD;
             carried out by the study;&#xD;
&#xD;
         14. Inability or unwillingness to fully comply with the research program;&#xD;
&#xD;
         15. Mentally or legally incapacitated;&#xD;
&#xD;
         16. The researchers believe that there are any other reasons why the subjects are unfit to&#xD;
             participate in the study;&#xD;
&#xD;
         17. Prescription was used within 14 days before the first administration or within 48&#xD;
             hours before the first administration;&#xD;
&#xD;
         18. Drugs that have used strong/intermediate inhibitors or induce liver drug metabolic&#xD;
             enzyme CYP3A4 14 days before the first administration or ingest grapefruit or related&#xD;
             products within 7 days before the first administration;&#xD;
&#xD;
         19. During the study, it was expected to use drugs that had an effect on P-gp or breast&#xD;
             cancer drug-resistant protein (BCRP)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Chen, M.D</last_name>
    <phone>0518-82342973</phone>
    <email>hong.chen@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Luo, Doctor</last_name>
      <phone>028-85423237</phone>
      <email>luozhu720@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>April 25, 2023</last_update_submitted>
  <last_update_submitted_qc>April 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

